Blog

  • Cheryl Gillan – 2016 Parliamentary Question to the Department of Health

    Cheryl Gillan – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Cheryl Gillan on 2016-05-19.

    To ask the Secretary of State for Health, what progress NHS England has made on including an indicator in the Mental Health Services Data Set recording a diagnosis of autism; and when data collection of such diagnoses is planned to commence.

    Alistair Burt

    NHS England has been working with the Health and Social Care Information Centre to develop reporting from the new Mental Health Services Data Set. This mandatory data set includes provision for the diagnosis of autism to be recorded, and reporting on this data has been prioritised. We expect experimental data reports on the number of people diagnosed with autism to be published by the end of 2016.

  • David Anderson – 2016 Parliamentary Question to the Department of Health

    David Anderson – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by David Anderson on 2016-05-19.

    To ask the Secretary of State for Health, how many meetings NHS England has had with PTC Therapeutics to discuss an agreement on price for Translarna to treat Duchenne muscular dystrophy since 15 April 2016.

    George Freeman

    NHS England has advised that on 4 May 2016 the National Institute for Health and Care Excellence (NICE) asked NHS England and PTC Therapeutics to continue to work towards agreeing an acceptable managed access arrangement for Translarna (ataluren) for the treatment of children aged five and over with Duchenne muscular dystrophy caused by a nonsense mutation.

    NHS England and the company have been asked to reach agreement on the cost of the drug to the National Health Service by 7 July.

    NHS England has advised there have not been any commercial meetings with PTC Therapeutics in the period since 15 April 2016, however, it is in regular contact with the company.

    NHS England will be meeting with PTC Therapeutics when it has concluded the detailed preparatory work required to effectively respond to NICE’s request within the set timescale.

  • Cheryl Gillan – 2016 Parliamentary Question to the Department of Health

    Cheryl Gillan – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Cheryl Gillan on 2016-05-19.

    To ask the Secretary of State for Health, what the average time taken for autism diagnosis was by age and gender at time of diagnosis for each year from 2013.

    Alistair Burt

    We do not centrally collect data from the National Health Service on waiting times for an assessment of autism.

    The National Institute for Health and Care Excellence clinical guideline on autism diagnosis states that a diagnostic assessment should start within 12 weeks of referral.

    NHS England and the Association of Directors of Social Services have undertaken a series of visits to clinical commissioning groups to identify best practice on diagnosis and support.

  • David Anderson – 2016 Parliamentary Question to the Department of Health

    David Anderson – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by David Anderson on 2016-05-19.

    To ask the Secretary of State for Health, what steps he is taking to ensure that NHS England implements the NICE recommendation for NHS funding for Translarna as a treatment for Duchenne muscular dystrophy.

    George Freeman

    The National Institute for Health and Care Excellence (NICE) is currently evaluating Translarna (ataluren) for the treatment of Duchenne muscular dystrophy through its highly specialised technology programme. The expected publication date for NICE’s final guidance is July 2016.

    National Health Service commissioners are legally required to fund drugs and treatments recommended in NICE highly specialised technology guidance within three months of its final guidance being issued.

  • John Glen – 2016 Parliamentary Question to the Department of Health

    John Glen – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by John Glen on 2016-05-19.

    To ask the Secretary of State for Health, with reference to his Answer of 9 May 2016 to Question 35866, what the capital spend by (a) the Health Protection Agency on its National Incident Coordination Centre in 2011 at Buckingham Palace Gate and (b) Public Health England on its National Emergency Operations Centre in Wellington House was in 2015.

    Jane Ellison

    Public Health England was established in 2013. Therefore the Department has not been able to specifically identify the historical costs of creating the National Incident Coordination Centre (NICC) in 2011.

    The works to install the NICC was part of a wider refit of 5th Floor North in Wellington House. The project cost for this refit was £43,000; the cost of installing the NICC cannot be specifically identified.

  • Alistair Carmichael – 2016 Parliamentary Question to the Department of Health

    Alistair Carmichael – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Alistair Carmichael on 2016-05-19.

    To ask the Secretary of State for Health, if he will make it his policy that when revised UK Chief Medical Officers’ Guidelines on keeping health risks from drinking alcohol to a low level, published in January 2016, are communicated to the public they are placed in the context that moderate alcohol consumption can be part of a healthy lifestyle for people that choose to drink.

    Jane Ellison

    The UK Chief Medical Officers’ alcohol guidelines give the public the latest and most up to date scientific information so that they can make informed decisions about their own drinking.

    It is however important that the new guidelines are clear and understandable and take into account the responses to the consultation.

    We will publish the final guidelines and the government response to the consultation as soon as possible.

  • Greg Mulholland – 2016 Parliamentary Question to the Department of Health

    Greg Mulholland – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Greg Mulholland on 2016-05-19.

    To ask the Secretary of State for Health, following the announcement on Twitter by the Parliamentary Under-Secretary of State for Life Sciences on 15 April 2016 that a Managed Access Agreement had been reached for the Translarna drug, for what reasons NICE granted a further eight weeks on 4 May 2016 for discussions to take place.

    George Freeman

    On 15 April 2016, the National Institute for Health and Care Excellence (NICE) announced in its final draft guidance that it was recommending Translarna (ataluren) for the treatment of children aged five and over with Duchenne muscular dystrophy caused by a nonsense mutation.

    Translarna was recommended only when (a) the company provides it at a discounted price to the National Health Service under the patient access scheme agreed with the Department and (b) that NHS England and the manufacturer, PTC Therapeutics, in conjunction with patient representatives, agree a managed access agreement setting out (i) the criteria for starting and stopping treatment, which individual patients would be required to agree, (ii) data collection to address considerable uncertainty in the evidence base and (iii) additional confidential financial controls between the company and NHS England.

    On 4 May 2016, NICE announced that it was allowing extra time for further discussions on access arrangements for Translarna to take place before its final guidance is published. NHS England and PTC Therapeutics have been asked to reach agreement on the cost of the drug to the NHS by 7 July 2016.

  • Greg Mulholland – 2016 Parliamentary Question to the Department of Health

    Greg Mulholland – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Greg Mulholland on 2016-05-19.

    To ask the Secretary of State for Health, whether purdah arrangements for the EU referendum apply to policy statements to be published by NHS England on the commissioning of treatments.

    George Freeman

    Whilst the pre-election guidance for the European Union referendum has yet to be published, it is not anticipated that it would prevent the routine publication of clinical commissioning policy statements which are a ‘business as usual’ function of NHS England.

    The Cabinet Office publishes pre-election guidance for civil servants which also applies to NHS England and other arm’s length bodies. This can be found at:

    https://www.gov.uk/government/publications/election-guidance-for-civil-servants

    “

  • Karl McCartney – 2016 Parliamentary Question to the Department of Health

    Karl McCartney – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Karl McCartney on 2016-05-19.

    To ask the Secretary of State for Health, how much the Government spent on prescriptions for people over the age of 60 in full-time employment in each of the last five years that figures are available.

    Alistair Burt

    The information is not available as the employment status of patients is not collected.

  • Jonathan Reynolds – 2016 Parliamentary Question to the Department of Health

    Jonathan Reynolds – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Jonathan Reynolds on 2016-05-19.

    To ask the Secretary of State for Health, how many patients currently in Assessment and Treatment Units have been diagnosed with autism.

    Alistair Burt

    At the end of April 2016 for inpatients with a learning disability and/or autism, the average length of stay was 1,095 days. The total number of inpatients was 2,565. 415 were diagnosed with autism only and 555 patients had a learning disability and autism (Learning Disability Services Monthly Statistics, April 2016).

    The average weekly cost for inpatient care was £3,563 per week in September 2015 (Learning Disability Census: England 2015)

    Both the Learning Disability Services Monthly Statistics and the Learning Disability Census provide data on people with learning disabilities and/or autism spectrum disorder receiving inpatient care commissioned in England.